Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts.

By E. Zeisberg, S. Potenta, L. Xie, M. Zeisberg, Raghu Kalluri. Cancer Research, 2007

980 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. (2009, background): “Fsp-1/ S100A4 has been extensively linked to the mesenchymal phenotype and is considered as a marker for EMT [43,44].”
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives (2021, background): “Through EMT and endothelial-to-mesenchymal transition (EndMT), most epithelial cells and endothelial cells can express a number of fibroblast markers, such as α-SMA and FAP [69, 70].”
In search of definitions: Cancer‐associated fibroblasts and their markers (2019, background): “Furthermore, FSP1 expression in fibroblasts is also strongly variable between different CAF sub-populations.(52) Other putative markers, such as Transgelin (TAGLN) and Periostin (POSTN), are also highly expressed in fibroblast and CAF populations(76) and have been used as secondary markers alongside”
Stroma Cells in Tumor Microenvironment and Breast Cancer (2012, positive): “Moreover, CAFs may arise from endothelial cells by the endothelial-tomesenchymal transition with CD31 loss and higher expression of α-SMA and fibroblast-specific protein (FSP)-1 [18].”